$TLSA

Jefferies says Parkinson’s drug development is shifting toward neuroinflammation, while still pursuing alpha-synuclein. It estimates the addressable early US and EU population could exceed 2 million by 2035, implying a ~$8 billion disease-modifying therapy market. It cites Roche’s prasinezumab missed endpoints twice but moved to Phase III, and Denali’s BIIB122 failed broadly. Companies mentioned include Ventyx (VTYX), BioVie (BIVI), and Tiziana (TLSA).

Elrifi Ivor (Chief Executive Officer) purchased 321,423 indirectly-held shares of Tiziana Life Sciences Ltd (TLSA) at an average of $0.99 ($0.97–$1.00, $0.32M total) across 2 trades over 2026-08-04 to 2026-08-05.

Elrifi Ivor (Chief Executive Officer) purchased 667,000 indirectly-held shares of Tiziana Life Sciences Ltd (TLSA) at $1.00 ($0.67M total) on 2026-08-03.

Friday’s US market ended higher, with the Nasdaq up about 1% to 25,373, the S&P 500 up 0.7% to 7,489, and the Dow up 0.5% to 52,485, led by a tech rebound. The article cites company updates including Roblox, Strategy (MSTR), Rivian, Reddit, and Coinbase after their Q2 results, plus clinical and rare-earth project news for several smaller firms.

Tiziana Life Sciences (NASDAQ: TLSA) reported quantitative PET imaging results from the third patient in its Phase 2 trial of intranasal foralumab for Multiple System Atrophy. The company said post-dosing scans showed reduced neuroinflammatory activity, including up to a 34% drop in SUV and 26% in SUVR. TLSA shares were up 6.19% to $1.04.

Tiziana Life Sciences (NASDAQ:TLSA) reported PET imaging results from a third multiple system atrophy patient completing dosing in its Phase 2 trial of intranasal foralumab. The company said quantitative PET analysis showed up to 34% reductions in SUV and 26% in SUVR in affected brain regions, similar to prior patients, and plans further patient evaluation.

BOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces quantitative PET imaging results from the third patient with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab to complete dosing.

Tiziana Life Sciences (NASDAQ:TLSA) said the last patient has received a first intranasal dose of foralumab in its Phase 2a trial for non-active secondary progressive multiple sclerosis (na-SPMS). The randomized, double-blind study targets up to 48 patients and compares two doses vs placebo. Topline data are expected late Q3/early Q4 2026, with results planned for October 2026.

Individual investors collectively hold 53% ownership in Tiziana Life Sciences Ltd, making them the largest shareholder group and giving them significant influence over management and business strategy. Insiders, particularly Gabriele Marco Cerrone who is the top executive, own a substantial 43% of the company, indicating strong alignment with the business's future. Institutional investment is currently less than 5%, suggesting potential growth if the company improves and attracts more institutional buyers.

BOSTON, Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Tiziana Life Sciences, Ltd. ( Nasdaq: TLSA ) ( "Tiziana" or the "Company" ) , a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal ...